TScan Therapeutics

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of two abstracts for poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4 in Chicago, IL as well as virtually.

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the underwriters of its previously announced public offering, which closed on April 19, 2024, have partially exercised their over-allotment option to purchase an additional 2,485,487 shares of its voting common stock at the public offering price of $7.13 per share, less underwriting discounts and commissions. After giving effect to the option closing, the total number of shares sold by the Company in the offering were 4,958,068 shares, which along with pre-funded warrants to purchase up to an aggregate of 18,577,419 shares of its voting common stock, resulted in aggregate gross proceeds to the Company of approximately $167.8 million before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

WALTHAM, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of one abstract for oral presentation and four abstracts for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11 in Baltimore, MD as well as virtually.

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

WALTHAM, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the closing of an underwritten public offering of 2,472,581 shares of its voting common stock at a public offering price of $7.1300 per share, which was equal to the closing price of its voting common stock on the Nasdaq Global Market on April 16, 2024, and pre-funded warrants to purchase up to an aggregate of 18,577,419 shares of its voting common stock at a price to the public of $7.1299 per pre-funded warrant to purchase one share of the voting common stock, which represents the per share public offering price for the voting common stock less the $0.0001 per share exercise price for each such pre-funded warrant. In addition, TScan has granted the underwriters a 30-day option to purchase up to an additional 3,157,500 shares of its voting common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to TScan from this offering were approximately $150.1 million, prior to any exercise of the underwriters' option to purchase additional shares of voting common stock and before deducting underwriting discounts and commissions and other estimated offering expenses payable by TScan.

TScan Therapeutics Announces Closing of Upsized Public Offering

WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 2,472,581 shares of its voting common stock at a public offering price of the market price of $7.1300 per share, which was equal to the closing price of its voting common stock on the Nasdaq Global Market on April 16, 2024, and pre-funded warrants to purchase up to an aggregate of 18,577,419 shares of its voting common stock at a price to the public of $7.1299 per pre-funded warrant to purchase one share of the voting common stock, which represents the per share public offering price for the voting common stock less the $0.0001 per share exercise price for each such pre-funded warrant. In addition, TScan has granted the underwriters a 30-day option to purchase up to an additional 3,157,500 shares of its voting common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to TScan from this offering are expected to be approximately $150.1 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by TScan, assuming no exercise of the underwriters' option to purchase additional shares of voting common stock. The offering is expected to close on or about April 19, 2024, subject to customary closing conditions.

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has commenced an underwritten public offering of $125 million of shares of its voting common stock and, in lieu of voting common stock, to certain investors that so choose, pre-funded warrants to purchase shares of voting common stock. All shares of voting common stock and pre-funded warrants to be sold in the offering will be offered by TScan. TScan intends to grant the underwriters a 30-day option to purchase additional shares of its voting common stock in an amount equal to 15% of the securities offered in the public offering. The offering is subject to market, regulatory and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for at least one TCR-T in the ImmunoBank and ~30% are eligible for multiplex therapy

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial development Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial development

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.

WALTHAM, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 2:15 p.m. Eastern Time.

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Brainsway

Crescent Point Energy

Genius Sports

Stereotaxis Inc

TransAlta

Taboola

Generally speaking, you want to minimize your exposure to cheap stocks under $10. Yes, smaller companies have the potential to rise dramatically higher than their larger counterparts.

Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.78 per share a year ago.

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates

Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the Tandem Meetings of ASTCT and CIBMTR; 8/8 (100%) patients in treatment arms are relapse-free and show complete donor chimerism

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate in the Cell Therapy Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference being held at the Marriott Copley Place in Boston on Wednesday, March 6, 2024 at 9:10 a.m. Eastern Time.

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

All eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or TSC-101

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

TScan Therapeutics, Inc. (TCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

TScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar?

TScan's abstract selected by the Tandem Meetings to receive a Best Abstracts Award Company to discuss the potential implications of initial data from a large prospective clinical trial assessing the relationship between donor chimerism and risk of relapse WALTHAM, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss updated results from its Phase 1 heme malignancies study and highlights from its oral presentation at the 2024 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood and Marrow Transplant Research (CIBMTR®) on Monday, February 26, 2024, at 8:00 a.m.

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

WALTHAM, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development. Dr. Pinchasik brings to TScan over a decade of experience in clinical development across the pharmaceutical and biotechnology industry.

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Jason A. Amello as Chief Financial Officer. Mr. Amello, a senior finance executive, brings to TScan nearly three decades of expertise in financial strategy, business development, and operations in the biotechnology industry.

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

Presentation to include additional results from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

Reported positive initial data from Phase 1 heme program at the 65 th American Society of Hematology (ASH) Annual Meeting

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

Prevention relapse data from phase 1 study, using TSC-100/TSC-101 for HLA A*02:01 positive AML, MDS, and ALL patients, is expected to be released in 2024. Results from T-Plex [multiple TCR-Ts] targeting patients' solid tumors in phase 1 study are expected to be released in 2024. Amgen's multi-year collaboration deal brought in an upfront $30 million payment, $500 million possible milestone payments, and tiered royalties; First targeting Crohn's Disease and possibly later Ulcerative Colitis.

TScan: Two 2024 TCR-T Data Readouts Could Bring Significant Value

No relapses have occurred in six of six treatment-arm patients, four with follow-up past six months; one of four control-arm patients relapsed at six months and two others required clinical intervention

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of R. Keith Woods to its Board of Directors. Mr. Woods has over 30 years of life science experience, with expertise in commercialization, sales, global operations, supply chain and business strategy.

TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations

TScan Therapeutics, Inc. (TCRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Recent Price Trend in TScan Therapeutics, Inc. (TCRX) is Your Friend, Here's Why

WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event on Monday, December 11, at 8:00 a.m. ET to discuss highlights from its poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. Following the prepared remarks, the call will be opened for a live question and answer session. To submit a question, please reach out to questions@lifesciadvisors.com.

TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition

News for TScan Therapeutics Stock (TCRX)